Phase II study of the IDH2- inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS)

7010Background: Isocitrate dehydrogenase 2 (IDH2) mutations occur in 5% of patients (pts) with MDS. Enasidenib (ENA) is a selective oral inhibitor of the mutant IDH2 enzyme with single-agent activi...